Open AccessA Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
Author(s) -
Martin Dreyling,
Constantine S. Tam,
Michael Wang,
Stephen D. Smith,
Marco Ladetto,
Huiqiang Huang,
William Novotny,
Melannie Co,
Adriana Romano,
Eric Holmgren,
Jane Huang,
Steven Le Gouill
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0794
Subject(s) - mantle cell lymphoma , bendamustine , medicine , rituximab , ibrutinib , bruton's tyrosine kinase , oncology , phases of clinical research , lymphoma , tyrosine kinase , clinical trial , chronic lymphocytic leukemia , leukemia , receptor
Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem cell transplant, leaving them with limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, are an effective treatment strategy in mantle cell lymphoma. Zanubrutinib is a potent next-generation Bruton tyrosine kinase inhibitor that has demonstrated complete and sustained Bruton tyrosine kinase occupancy, minimal off-target effects and favorable pharmacokinetic/pharmacodynamic properties. Described herein is an ongoing Phase III study comparing the efficacy and safety of zanubrutinib plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation in transplant-ineligible patients with previously untreated mantle cell lymphoma. Clinical Trial Registration: NCT04002297 ( ClinicalTrials.gov )